Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.43 Average Target Price from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $16.43.

A number of equities analysts recently issued reports on ELAN shares. UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. Leerink Partners began coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Finally, Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors have recently bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC bought a new stake in Elanco Animal Health during the third quarter valued at about $29,000. AM Squared Ltd purchased a new position in Elanco Animal Health in the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health during the third quarter valued at about $35,000. Finally, Quarry LP bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $40,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.7 %

NYSE ELAN opened at $11.47 on Friday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 52 week low of $11.11 and a 52 week high of $18.80. The firm has a market capitalization of $5.67 billion, a price-to-earnings ratio of 28.68, a PEG ratio of 1.96 and a beta of 1.41. The company has a fifty day moving average of $12.66 and a two-hundred day moving average of $13.43.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm posted $0.18 EPS. The firm’s revenue was down 3.6% compared to the same quarter last year. On average, analysts predict that Elanco Animal Health will post 0.92 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.